U.S. Markets closed

Amneal Pharmaceuticals Inc (AMRX) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Amneal Pharmaceuticals Inc (AMRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Amneal Pharmaceuticals Inc has a market cap of $4.03 billion; its shares were traded at around $13.50 .

For the last quarter Amneal Pharmaceuticals Inc reported a revenue of $497.5 million, compared with the revenue of $259.9 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.7 billion,

The reported loss per diluted share was 16 cents for the year. The Amneal Pharmaceuticals Inc had a decent operating margin of 14.21%, compared with the operating margin of % a year before. The profitability rank of the company is 3 (out of 10).

At the end of the fiscal year, Amneal Pharmaceuticals Inc has the cash and cash equivalents of $213.4 million. The long term debt was $2.6 billion. The interest coverage to the debt is 4.6. Amneal Pharmaceuticals Inc has a financial strength rank of 3 (out of 10).

For the complete 20-year historical financial data of AMRX, click here.

This article first appeared on GuruFocus.